



Correction: Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates hepatotoxicity via phase I and II drug metabolizing enzymes

Hakkim, F. L., Bakshi, H. A., Khan, S., Nasef, M. M., Farzand, R., Sam, S., Rashan, L., Al-Baloshi, M. S., Abdo Hasson, S. S., Jabri, A. A., McCarron, P. A., & Tambuwala, M. M. (2020). Correction: Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates hepatotoxicity via phase I and II drug metabolizing enzymes. *Oncotarget*, 11(23), 2259-2261. <https://doi.org/10.18632/oncotarget.27540>

[Link to publication record in Ulster University Research Portal](#)

Published in:
Oncotarget

Publication Status:
Published (in print/issue): 09/06/2020

DOI:
[10.18632/oncotarget.27540](https://doi.org/10.18632/oncotarget.27540)

Document Version
Publisher's PDF, also known as Version of record

Document Licence:
CC BY

General rights

The copyright and moral rights to the output are retained by the output author(s), unless otherwise stated by the document licence.

Unless otherwise stated, users are permitted to download a copy of the output for personal study or non-commercial research and are permitted to freely distribute the URL of the output. They are not permitted to alter, reproduce, distribute or make any commercial use of the output without obtaining the permission of the author(s).

If the document is licenced under Creative Commons, the rights of users of the documents can be found at <https://creativecommons.org/share-your-work/licenses/>.

Take down policy

The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact pure-support@ulster.ac.uk

Correction

Correction: Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates hepatotoxicity via phase I and II drug metabolizing enzymes

Faruck L. Hakkim^{1,6,*}, Hamid A. Bakshi^{2,3,8,*}, Shabia Khan³, Mohamed M. Nasef², Rabia Farzand⁴, Smitha Sam⁵, Luay Rashaan¹, Mohammed S. Al-Baloshi⁷, Sidgi Syed Anwar Abdo Hasson⁷, Ali Al Jabri⁷, Paul A. McCarron⁸ and Murtaza M. Tambuwala⁸

¹Frankincense Biodiversity Unit, Research Center, Dhofar University, Salalah, Oman

²Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield, United Kingdom

³Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, USA

⁴Department of Clinical and Pharmaceutical Sciences, University of Hertfordshire, Hertfordshire, United Kingdom

⁵Chemotherapy Unit, St. Jude Clinics-Center for Cancer Treatment, Pathanamthitta, Kerala, India

⁶Department of Mathematics and Sciences, College of Arts and Applied Sciences, Dhofar University, Salalah, Oman

⁷Department of Microbiology and Immunology, College of Medicine and Health Sciences, Sultan Qaboos University, Al-Khoud, Muscat, Oman

⁸School of Pharmacy and Pharmaceutical Science, SAAD Centre for Pharmacy and Diabetes, Ulster University, Coleraine, County Londonderry, Northern Ireland, United Kingdom

*These authors contributed equally to this work and should be considered as first authors

Published: June 09, 2020

Copyright: Hakkim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to errors during image selection, identical images were used for panels D and E in Figure 1D. In Figure 7A, the brain images for 'healthy' and 'treated' are also accidental duplicates. Additionally, the name of the 4th author in the listing has been updated, correcting the name as follows:

Mohamed M. Nasef²

The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2019; 10:3472–3490. <https://doi.org/10.18632/oncotarget.26930>

D




Figure 1: Cytotoxicity of FEO on B16-F10, FM94 and HNEM cells. (D) FM94 cells treated with FEO (A-Untreated cells; B-3 µg/ml; C-5 µg/ml; D-7 µg/ml; E-10 µg/ml; F- Dox 5 µg/ml) for 24 h and morphological image was photographed by EVOS image analyser; E: HNEM cells treated with FEO (A-Untreated cells; B-3 µg/ml; C-5 µg/ml; D-7 µg/ml; E-10 µg/ml; F- Dox 5 µg/ml) for 24 h and morphological image was photographed by EVOS image analyser. Data presented as mean \pm SD of triplicates of three independent experiments. *Represents significant difference at $p < 0.05$ compared with control. **Represents significant difference at $p < 0.01$ compared with control. ***Represents significant difference at $p < 0.001$ compared with control. NS: Non significant. Scale bar indicates 10 µm.




Figure 7: *In vivo* toxicity of FEO on major organs: Mice were treated with FEO (1200 mg/kg body weight). At the end of experimental period major organs such as brain, heart, liver and kidney were excised and stained with hemotoxylin and eosin. Scale bar indicates 10 µm.